1098-1136/asset/olbannerleft.gif?v=1&s=e6cb8ca99635b2d8dee48149272e1b077a90e920)
1098-1136/asset/olbannerright.gif?v=1&s=dc97874dbe766e01003f28699692b2a04222fcbd)
Review
Cancer stem cells in gliomas: Identifying and understanding the apex cell in cancer's hierarchy
Article first published online: 5 MAY 2011
DOI: 10.1002/glia.21185
Copyright © 2011 Wiley-Liss, Inc.
Additional Information
How to Cite
Venere, M., Fine, H. A., Dirks, P. B. and Rich, J. N. (2011), Cancer stem cells in gliomas: Identifying and understanding the apex cell in cancer's hierarchy. Glia, 59: 1148–1154. doi: 10.1002/glia.21185
Publication History
- Issue published online: 2 JUN 2011
- Article first published online: 5 MAY 2011
- Manuscript Accepted: 8 APR 2011
- Manuscript Received: 17 JAN 2011
Funded by
- National Brain Tumor Society, Goldhirsh Foundation
- NIH. Grant Numbers: NS054276, CA129958, CA116659, CA154130
- National Research Service Awards. Grant Number: NS058042
- Damon Runyon Cancer Research Foundation
- American Brain Tumor Association Basic Research Fellowship
- Canadian Cancer Society Research Institute
- Canadian Institutes for Health Research
- Ontario Institute for Cancer Research
- Terry Fox Foundation
- Hospital for Sick Children Foundation
- Jessica's Footprint Foundation
- National Cancer Institute
- National Institutes of Neurological Disorders
- Stroke/National Institutes of Health
- Abstract
- Article
- References
- Cited By
Keywords:
- glioma;
- cancer stem cell;
- therapy resistance
Abstract
Neuro-oncology research has rediscovered a complexity of nervous system cancers through the incorporation of cellular heterogeneity into tumor models with cellular subsets displaying stem-cell characteristics. Self-renewing cancer stem cells (CSCs) can propagate tumors and yield nontumorigenic tumor bulk cells that display a more differentiated phenotype. The ability to prospectively isolate and interrogate CSCs is defining molecular mechanisms responsible for the tumor maintenance and growth. The clinical relevance of CSCs has been supported by their resistance to cytotoxic therapies and their promotion of tumor angiogenesis. Although the field of CSC biology is relatively young, continued elucidation of the features of these cells holds promise for the development of novel patient therapies. © 2011 Wiley-Liss, Inc.